Navigation Links
Cellana to Provide Commercialization and Technology Updates at the 2013 Algae Biomass Summit
Date:9/26/2013

SAN DIEGO and KAILUA-KONA, Hawaii, Sept. 26, 2013 /PRNewswire/ -- Cellana, a leading developer of algae-based feedstocks for biofuels, animal feed/food, and Omega-3 nutritional oils, announced today that several key personnel will present at the upcoming 2013 Algae Biomass Summit.  The 2013 event will take place Sept. 30 – Oct. 3 at the Hilton Orlando in Orlando, Florida, and Cellana will be exhibiting at Booth #205 in the Exhibit and Poster Hall. 

  • Martin A. Sabarsky, Cellana's Chief Executive Officer, will present at a plenary panel entitled, "The Algae Fuel Solution - Updates from Algenol Biofuels, Sapphire Energy, and Cellana," which is scheduled for Tuesday, Oct. 1 at 8:45 am.  During the presentation, Mr. Sabarsky will provide an update on Cellana's progress since the last Summit, including details of Cellana's industry-leading off-take agreement with Neste Oils for biofuel applications, which was announced earlier this year.
  • Xuemei Bai, Ph.D., Principal Scientist for Cellana, will present at a Commercialization Track panel (Track 3) entitled "Production Process Innovation," which is scheduled for Wednesday, Oct. 2 at 3:30 pm in the Orlando Ballroom IV. During her presentation, Dr. Bai will discuss how Cellana has advanced its commercialization objectives through increased productivity of biomass and high-value co-products.
  • Michael J. Kamdar, Cellana's President, will present at a plenary panel entitled "Algae and Finance," 
which is scheduled for Thursday, Oct. 3 at 9:00 am. During his presentation, Mr. Kamdar will discuss how Cellana has benefitted from an over $100 million investment in its technology platform and Kona Demonstration Facility, including the $80+ million in non-dilutive funding received to date from strategic partners, grants, and government contracts. In addition, Mr. Kamdar will discuss the company's financing plans going forward.
  • Avery Kramer, Cellana's Business Development Manager, will present Cellana's poster submission throughout the Summit.  Entitled "Supporting Biofuels through Production of High-Value Co-Products," the poster will contain updated technoeconomic information that supports Cellana's three-product biorefinery model.

The Algae Biomass Summit brings industry professionals from all sectors of the world's algae utilization industries including, but not limited to, financing, algal ecology, genetic systems, carbon partitioning, engineering, analysis, biofuels, animal feeds, fertilizers, bioplastics, supplements, and foods. Organized by the Algae Biomass Organization and coproduced by BBI International, the event brings current and future producers of bio-based products and energy together with algae crop growers, municipal leaders, technology providers, equipment manufacturers, project developers, investors, and policy makers. As the largest, fastest-growing algae event of its kind, in 2013 the Summit is expected to draw nearly 1,000 attendees. 

For more information on the event, visit the Algae Biomass Summit website at http://www.algaebiomasssummit.org.

About Cellana

Cellana, a leading developer of algae-based bioproducts, uses the most productive plants on earth — marine microalgae — to photosynthetically produce its ReNew™ line of Omega-3 EPA and DHA oils, animal feed/food, and biofuel feedstocks.  Cellana's patented ALDUO™ system enables economic, sustainable and consistent production of photosynthetic, non-GMO algae at industrial scale. Cellana intends to construct and operate commercial facilities to produce these products as integrated algae-based biorefineries. To date, over $100 million has been invested in developing Cellana's algae strains, patented and proprietary production technologies, and its Kona Demonstration Facility. Further information is available at: www.cellana.com.

Cellana®, the Cellana logo, ALDUO, and ReNew are trademarks of Cellana LLC and/or Cellana, Inc. 


'/>"/>
SOURCE Cellana
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. New Resource Provides Herb Industry With Sources of Quality Specifications
2. inVentiv Health Selected to Provide Sales Operations Support for Santarus
3. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
4. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
5. Health Diagnostic Laboratory, Inc. Provides Largest Corporate Gift in Science Museum of Virginias History
6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
7. Elsevier Acquires QUOSA, Provider of Life Sciences Content Management and Workflow Productivity Solutions
8. Oxford Finance Provides $15 Million Senior Secured Credit Facility to Private Equity Backed Healthcare Services Company
9. Insmed Incorporated Provides Corporate Update
10. Swiss, EMA, US Pharmacopoeia and World Health Organization Authorities to Provide an Update on Cool Chain Regulations
11. Van Andel Research Institute Study Provides New Details of Fundamental Cellular Process
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):